TMCnet News
Research and Markets: Global Oncology Biosimilars Market 2014-2018 with Biocon, Celltrion, Dr. Reddy's Laboratories, Hospira, Mylan & Sandoz DominatingDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/lwkjtl/global_oncology) has announced the addition of the "Global Oncology Biosimilars Market 2014-2018" report to their offering. The Global Oncology Biosimilars market to grow at a CAGR of 29.87% over the period 2013-2018. Biosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the original product. Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncolog in the supportive care setting are known as oncology biosimilars. One key trend in this market is the outsourcing of biosimilar manufacturing activities to developing countries. Outsourcing the manufacture of biosimilar products decreases the overall cost of manufacturing biosimilars, thereby making them affordable to patients. According to the report, one of the main drivers of the market is the increase in the number of patent expiries. A number of biopharmaceutical patents are either about to expire in the near future or have already expired. This has helped propel the growth of vendors in the market. Further, the report states that one of the major challenges that the market faces is the risk related to the failure of the drug in the market. The high investment required during the developmental stage of drugs creates risks for vendors. Key Vendors
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/lwkjtl/global_oncology
|
